GHRH Analog Research Guide

Sermorelin:
The Original
GHRH Analog

The first FDA-approved growth hormone releasing hormone analog. A guide to Sermorelin's mechanism, clinical research, and place among modern peptide therapies.

How It Works Compare Peptides
SermorelinGuide icon
✓
FDA-approved (1997–2008)
✓
29-amino acid GHRH(1-29) analog
✓
Preserves pituitary feedback
✓
Extensive human clinical data
✓
Available via compounding pharmacies
⚠️

This site is for informational purposes only. While Sermorelin was previously FDA-approved, it is now primarily available through compounding pharmacies for off-label use. Consult a licensed physician for any clinical decisions.

Quick Reference

Sermorelin at a Glance

Structure
GHRH(1-29)
The first 29 amino acids of human GHRH. Sufficient for full biological activity.
Half-Life
~10–20 min
Short half-life allows precise timing and preserves natural feedback regulation.
FDA History
1997
Approved for pediatric GH deficiency. Withdrawn from market in 2008 for commercial reasons — not safety.
vs. HGH
Indirect
Stimulates endogenous GH release vs. direct exogenous GH administration. Feedback loop preserved.

How It Works

Mechanism of Action

Sermorelin Pituitary GHRH-R GH Pulse Liver → IGF-1 Feedback Downstream Effects
01
GHRH Receptor Activation
Sermorelin binds the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary, triggering intracellular signaling cascades via cAMP and protein kinase A.
02
Pulsatile GH Release
The pituitary releases growth hormone in a pulsatile pattern that mirrors physiological GH secretion — preserving the natural rhythm rather than creating supraphysiological flat-line elevations.
03
IGF-1 Production
Elevated GH stimulates hepatic IGF-1 synthesis. IGF-1 mediates most of the growth-promoting effects on peripheral tissues including muscle, bone, and connective tissue.
04
Somatostatin Feedback Preserved
Unlike direct GH administration, Sermorelin allows somatostatin (the natural GH brake) to remain functional. This feedback loop is considered a key safety advantage — the body regulates against excess.

Clinical Profile

Why Sermorelin Matters

🏥
FDA-Approved History
One of the few peptides with an actual FDA approval history — approved 1997 for pediatric GHD, withdrawn 2008 for commercial reasons, not safety concerns. Substantial human clinical data exists.
🔄
Pituitary Preservation
Sermorelin stimulates rather than replaces endogenous GH production. Unlike exogenous GH, it does not suppress pituitary function — some research suggests it may actually restore sensitivity over time.
⚖️
Natural Feedback Loop
Somatostatin regulation remains active, providing a natural ceiling on GH elevations. This is cited as a primary safety differentiator vs. direct GH administration.
💤
Sleep Protocol
Most research protocols administer Sermorelin before bed, capitalizing on the natural nocturnal GH surge. This timing amplifies the physiological GH pulse that occurs during slow-wave sleep.
📋
Prescribable
Sermorelin is legally prescribed by licensed physicians through compounding pharmacies in the US, making it more accessible than many research peptides that lack any regulatory framework.
🧬
Anti-Aging Research
Sermorelin has been studied for age-related GH decline (somatopause). Research has examined improvements in body composition, sleep quality, bone density, and quality of life markers in aging populations.

GHRH Analogs

Sermorelin vs. Alternatives

PeptideTypeHalf-LifeFDA HistoryPituitary FeedbackKey Advantage
SermorelinGHRH(1-29)~10–20 minApproved (1997)PreservedClinical track record
CJC-1295 (DAC)GHRH analog~8 daysResearch onlyPreservedExtended half-life
CJC-1295 (no DAC)GHRH analog~30 minResearch onlyPreserved+Ipamorelin synergy
TesamorelinGHRH analog~26 minFDA ApprovedPreservedHIV lipodystrophy approved
Exogenous HGHDirect GH~15–30 minMultiple approvalsSuppressedMost data, most potent
MK-677GHS (oral)~24 hrResearch onlyPartialOral bioavailability
The original.
Still relevant.

In an era of newer, longer-acting GHRH analogs, Sermorelin remains relevant for one key reason: it has more human clinical data behind it than almost any other peptide in this class — accumulated during and since its FDA approval period.

PubMed Research →